ProImmune Ltd., a leader in services for understanding immune responses, announced today that it has launched ProArray Ultra™, a uniquely powerful protein and peptide array platform, which is more sensitive than optimized ECL ELISA. The new platform allows analysis of more than 30,000 peptides or proteins at once, and typically requires only 1ul of analyte sample. With its sensitivity and flexibility, ProArray Ultra overcomes the traditional trade-off between optimized 96-well plate-based assays, which are reliable and have good performance characteristics but lack the required throughput, and high throughput array technologies, which are typically only semi-quantitative.
Crucially, the ProArray Ultra array platform is all encompassing. Completely flexible design parameters can accommodate thousands of peptides and proteins on an array for initial exploration high throughput screening, and then multiple replicates of validated markers for small-scale analytical characterization later in the program.
Analysis with ProArray Ultra is provided by ProImmune to customers as a turnkey service and will enable a new broad range of research programs that are in many cases simply not feasible with existing approaches. Applications include antigen and monoclonal antibody characterization, analysis of serum antibody specificity, correlation of antibody responses with disease onset, progression and outcome, protein-protein interaction site mapping, iterative peptide and protein design, and general bioassay design.
Dr. Nikolai Schwabe, CEO of ProImmune, said "ProArray Ultra combines scale, flexibility, power and precision in a way that is unmatched by multi-well assay and other protein array formats available today. It demonstrates ProImmune's commitment to deliver unique solutions to our customers, providing accurate data and saving them a significant amount of time, money and project risk."
An ActRIIA fusion protein got FDA approved for PAH treatment